Group 1: Fudan Zhangjiang - Fudan Zhangjiang is advancing its DC platform and photodynamic technology platform, with multiple antibody-drug conjugates in various clinical stages for treating cancers such as triple-negative breast cancer, bladder cancer, and gastric cancer [1] - The company is conducting Phase III clinical studies for anti-Trop2 antibody-drug conjugates and has completed the first subject enrollment for a clinical trial involving aminolevulinic acid granules for non-muscle invasive bladder cancer [1] - Fudan Zhangjiang plans to increase R&D investment to further promote the progress of its research projects [1] Group 2: Xiangyu Medical - Xiangyu Medical's research indicates a clear and significant demand for non-invasive brain-machine interfaces in rehabilitation, sleep monitoring, and attention enhancement [2] - The company has developed two EEG collection devices that have received Class II medical device registration and expects to obtain multiple registrations for brain-machine interface products in the second half of the year [2] - Xiangyu Medical's sales strategy involves starting with top-tier hospitals and gradually expanding to lower-tier hospitals and community health centers, with plans to enter the home market [2]